Caribou Biosciences, Inc. - 8-K Filing

Caribou Biosciences announces restructuring, discontinuation of allogeneic CAR-T programs vispa-cel and CB-011, workforce reduction, and evaluation of strategic alternatives. (Items: 2.05 Costs Associated with Exit or Disposal Activities, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 8.01 Other Events)

SEC EDGAR ·

Tickers: $CRBU

Read the full article at SEC EDGAR

Part of the story TriplePoint Venture Growth BDC Corp. - 8-K Filing (197 articles)

More Regulatory news